Cetrorelix, sold under the brand name Cetrotide®, is a synthetic decapeptide and a gonadotropin-releasing hormone (GnRH) antagonist. It is primarily used in assisted reproductive technology (ART), specifically in in vitro fertilization (IVF).
Mechanism of Action: Cetrorelix works by competitively blocking GnRH receptors in the pituitary gland. This action suppresses the production and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). By preventing the premature LH surge, Cetrotide allows for better control of ovarian stimulation during ART. Premature LH surges can lead to premature ovulation, which can compromise egg retrieval and subsequent fertilization.
Clinical Use: Its main application is during controlled ovarian hyperstimulation (COH) for ART procedures such as IVF. Cetrorelix is administered subcutaneously, typically starting on day 5 or 6 of stimulation, and is continued until the day of human chorionic gonadotropin (hCG) administration (which triggers final oocyte maturation). The timing of initiation depends on the individual patient's ovarian response.
Benefits: Using a GnRH antagonist like Cetrorelix offers several advantages in ART cycles:
Side Effects: Common side effects may include:
Rare but more serious side effects can occur, and individuals should consult with their healthcare provider for a complete list and any concerns.
Contraindications: Cetrorelix is contraindicated in certain conditions, including:
Important Note: Cetrorelix should only be used under the guidance of a qualified fertility specialist. The information provided here is for general knowledge and does not substitute for professional medical advice.
Ne Demek sitesindeki bilgiler kullanıcılar vasıtasıyla veya otomatik oluşturulmuştur. Buradaki bilgilerin doğru olduğu garanti edilmez. Düzeltilmesi gereken bilgi olduğunu düşünüyorsanız bizimle iletişime geçiniz. Her türlü görüş, destek ve önerileriniz için iletisim@nedemek.page